FBR still bullish on Novavax after publication of data from vaccine study

Novavax's (NVAX) RSV vaccine is "under-appreciated," FBR says, adding that the company's pandemic vaccine program is "even less well appreciated."

The new note largely echoes similar research out last month, but analyst William Tanner's language regarding the company's pandemic program looks a bit more upbeat. "Investors should ignore the program no more," Tanner says, adding that "contrary to the belief that [recent AH7N9] data had already been released, they were, in fact, a new disclosure."

NVAX is rated Outperform.

Price target remains $11.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs